For Teva Pharmaceutical, generic is designer chic


The pharmaceutical sector, due to its complexity, is not for the novice investor. Further, not every pharmaceutical company represents a defensive pick. But one that meets the bar, due to its niche, is Teva Pharmaceutical.

Teva Pharmaceutical Industries Ltd. (ADR) (Nasdaq: TEVA), via an assertive product development program and acquisition schedule, has achieved a leadership position in the global generic segment.

Through a U.S. subsidiary Teva makes generic versions of brand-name antibiotics, heart drugs, and heartburn medications, among other drugs. The company boasts a 150-drug portfolio, including generics for blockbusters Prozac and Mevacor.

Analysts see a 13-16% revenue gain for Teva in 2008, on top of a solid 9-11% in 2007. Analysts also see 25-30 new generic launches in 2008 for Teva, which is also Israel's top drugmaker. The Reuters fiscal year (FY) 2007/F2008 earnings per share (EPS) consensus estimates for TEVA are $2.35 to $2.66.

Further, Teva's defensive status stems from the U.S. market's effort to limit drug spending increases: a considerable portion of health care cost increases could be eliminated via drug cost containment - - and generic drugs will help both public and private officials achieve this goal. Moreover, look for other developed world countries to seek to limit drug spending increases as well, in the decade ahead.

The risks? Analysts are watchful for intensifying competition, and unfavorable regulation changes that might hamper Teva's ability to sell its products.

The First Call mean rating for TEVA is: Buy [26 firms]. Mean 2008 target: $50.00 [high: $55, low: $46].

Stock Analysis: Teva Pharmaceutical is a moderate-risk stock not suitable for low-risk investors. Investors with an investment horizon longer than 2 years should be rewarded from TEVA's shares. Sell/Stop Loss if you were to purchase shares in this company: $27.

Disclosure: Lazzaro has no positions in stocks. In addition to private real estate holdings, he owns corporate and municipal bonds, and cash certificates of deposit.
Symbol Lookup
IndexesChangePrice
DJIA0.0012,801.23
NASDAQ0.002,903.88
S&P 5000.001,342.64

Last updated: February 13, 2012: 09:06 AM

Hot Stocks

General Electric

18.8750.00(0.00)

Alcoa

10.290.00(0.00)

Apple Inc

493.420.00(0.00)

Google Inc 'A'

605.910.00(0.00)

Bank of America

8.070.00(0.00)

Wal-Mart Stores

61.900.00(0.00)

Exxon Mobil Corp

83.800.00(0.00)

Ford

12.440.00(0.00)

Citigroup

32.9250.00(0.00)

IBM

192.420.00(0.00)

Yahoo

16.140.00(0.00)

Starbucks

48.820.00(0.00)

Microsoft

30.4950.00(0.00)

Home Depot

45.330.00(0.00)

DailyFinance Headlines

Benzinga Headlines

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

DailyFinance BlackBerry App

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

BioHealth Investor Headlines

Page Loaded in 1329142011019 ms.